Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis

Objective: To investigate the pharmacokinetics, pharmacodynamics, and exposure–response of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with generalized myasthenia gravis (gMG). Methods: The analysis used data from 62 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Monteleone, Jonathan P. R., Gao, Xiang, Kleijn, Huub Jan, Bellanti, Francesco, Pelto, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594444/
https://www.ncbi.nlm.nih.gov/pubmed/34795626
http://dx.doi.org/10.3389/fneur.2021.696385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594444/
https://www.ncbi.nlm.nih.gov/pubmed/34795626
http://dx.doi.org/10.3389/fneur.2021.696385

Ejemplares similares